CareDx, Inc (NASDAQ:CDNA) Holdings Decreased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 71.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,268 shares of the company's stock after selling 240,380 shares during the quarter. Cubist Systematic Strategies LLC owned 0.18% of CareDx worth $2,061,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Thompson Davis & CO. Inc. raised its stake in CareDx by 6.3% during the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after acquiring an additional 950 shares in the last quarter. Hsbc Holdings PLC raised its stake in CareDx by 6.9% during the 4th quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock valued at $365,000 after acquiring an additional 1,109 shares in the last quarter. Legal & General Group Plc raised its stake in CareDx by 1.3% during the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after acquiring an additional 1,118 shares in the last quarter. Sterling Capital Management LLC raised its stake in CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after acquiring an additional 1,151 shares in the last quarter.

Insider Buying and Selling

In related news, Director Christine Cournoyer sold 16,700 shares of CareDx stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the transaction, the director now directly owns 37,045 shares in the company, valued at $523,445.85. The trade was a 31.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Peter Maag sold 13,281 shares of CareDx stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director now owns 316,743 shares in the company, valued at $5,457,481.89. This represents a 4.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,382 shares of company stock worth $934,509 in the last three months. 4.90% of the stock is currently owned by insiders.

CareDx Stock Performance

Shares of CDNA stock traded up $0.08 during mid-day trading on Thursday, hitting $16.10. 1,684,588 shares of the stock traded hands, compared to its average volume of 877,911. CareDx, Inc has a twelve month low of $12.90 and a twelve month high of $34.84. The firm has a market cap of $896.46 million, a price-to-earnings ratio of -5.96 and a beta of 2.27. The company's 50-day simple moving average is $17.68 and its 200-day simple moving average is $21.02.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analysts' expectations of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) EPS. Analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CDNA shares. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and cut their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. StockNews.com cut CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group lowered their price target on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Finally, Stephens reiterated an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.